Paweł Krawczyk (Pawel Krawczyk)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Systematic Review

Cerebrospinal Fluid

Epidermal Growth Factor Receptor

Ejection Fraction

Top Venues

Annals of medicine

Scientific reports

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Michał Gil, Magdalena Knetki-Wroblewska, Przemysław Niziński, Maciej Strzemski, Paweł Krawczyk
Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients. Annals of medicine 55 (1) (2023)
Michał Gil, Magdalena Knetki-Wroblewska, Przemysław Niziński, Maciej Strzemski, Paweł Krawczyk
Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients. Annals of medicine 55 (1) (2023)
Justyna Błach, Małgorzata Frąk, Paweł Krawczyk, Juliusz Pankowski, Adam Pankowski, Jarosław Buczkowski, Artur Szlubowski, Jan Siwiec, Piotr Krudyś, Marek Michnar, Robert Kieszko, Janusz Milanowski
Observational cross-sectional study of 5279 bronchoscopy results for the practical effectiveness of various biopsy techniques in the diagnosis of lung diseases with particular emphasis on lung cancer. BMJ open 11 (8) (2021)
Paweł Krawczyk, Anna Grenda, Paulina Terlecka, Justyna Błach, Kamila Wojas-Krawczyk, Tomasz Kucharczyk, Izabela Chmielewska, Robert Kieszko, Bożena Jarosz, Michał Gil, Katarzyna Reszka, Janusz Milanowski
Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. Scientific reports 11 (1) (2021)
Anna Grenda, Justyna Błach, Michał Szczyrek, Paweł Krawczyk, Marcin Nicoś, Barbara Kuźnar Kamińska, Monika Jakimiec, Grażyna Balicka, Izabela Chmielewska, Halina Batura-Gabryel, Marek Sawicki, Janusz Milanowski
Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients. Cancer medicine 9 (2) (2019)